Aligos Therapeutics, Inc.

NasdaqCM:ALGS Stock Report

Market Cap: US$127.1m

Aligos Therapeutics Management

Management criteria checks 3/4

Aligos Therapeutics' CEO is Larry Blatt, appointed in Feb 2018, has a tenure of 6.92 years. total yearly compensation is $1.34M, comprised of 43.7% salary and 56.3% bonuses, including company stock and options. directly owns 2.32% of the company’s shares, worth $2.94M. The average tenure of the management team and the board of directors is 5.5 years and 3.8 years respectively.

Key information

Larry Blatt

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage43.7%
CEO tenure6.9yrs
CEO ownership2.3%
Management average tenure5.5yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Aligos Therapeutics: Promising Pipeline With Cash And Dilution Risks

Dec 11

Can Aligos Therapeutics (NASDAQ:ALGS) Afford To Invest In Growth?

Nov 27
Can Aligos Therapeutics (NASDAQ:ALGS) Afford To Invest In Growth?

Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 49% Though Its Price And Business Still Lag The Industry

Jul 31
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 49% Though Its Price And Business Still Lag The Industry

Aligos Therapeutics (NASDAQ:ALGS) Will Have To Spend Its Cash Wisely

Jul 16
Aligos Therapeutics (NASDAQ:ALGS) Will Have To Spend Its Cash Wisely

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 27% Dip In Price Shows Sentiment Is Matching Revenues

May 24
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 27% Dip In Price Shows Sentiment Is Matching Revenues

Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Apr 09
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues

Feb 23
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues

Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Oct 24
Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

Jul 17
We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

Mar 11
We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

Aligos Therapeutics begins 12-week dosing in phase 1b study to treat hepatitis B

Jul 25

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Jul 11
We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Feb 02
We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Oct 19
Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Aligos Therapeutics EPS beats by $0.16

May 10

We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash Wisely

May 01
We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash Wisely

CEO Compensation Analysis

How has Larry Blatt's remuneration changed compared to Aligos Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$77m

Jun 30 2024n/an/a

-US$76m

Mar 31 2024n/an/a

-US$100m

Dec 31 2023US$1mUS$587k

-US$88m

Sep 30 2023n/an/a

-US$82m

Jun 30 2023n/an/a

-US$82m

Mar 31 2023n/an/a

-US$83m

Dec 31 2022US$2mUS$549k

-US$96m

Sep 30 2022n/an/a

-US$112m

Jun 30 2022n/an/a

-US$126m

Mar 31 2022n/an/a

-US$136m

Dec 31 2021US$873kUS$549k

-US$128m

Sep 30 2021n/an/a

-US$125m

Jun 30 2021n/an/a

-US$125m

Mar 31 2021n/an/a

-US$116m

Dec 31 2020US$7mUS$493k

-US$109m

Sep 30 2020n/an/a

-US$92m

Jun 30 2020n/an/a

-US$73m

Mar 31 2020n/an/a

-US$62m

Dec 31 2019US$674kUS$475k

-US$52m

Compensation vs Market: Larry's total compensation ($USD1.34M) is above average for companies of similar size in the US market ($USD645.37K).

Compensation vs Earnings: Larry's compensation has been consistent with company performance over the past year.

CEO

Larry Blatt (62 yo)

6.9yrs

Tenure

US$1,344,458

Compensation

Dr. Lawrence M. Blatt, also known as Larry, Ph D., MBA, has been Chief Executive Officer and Director at Aligos Therapeutics, Inc. since February 2018 and also has been its Chairman of the Board since June...

Leadership Team

NamePositionTenureCompensationOwnership
Lawrence Blatt
CEO, President & Chairman of the Board6.9yrsUS$1.34m2.32%
$ 2.9m
Julian Symons
Executive VP & Chief Scientific Officer6.7yrsUS$836.32k0.42%
$ 539.7k
Lesley Calhoun
Executive VP & CFO4.6yrsno datano data
Kristina Engeseth
VP and Head of People & Culture3yrsno datano data
Sushmita Chanda
Executive Vice President & Chief Development Officer6.4yrsno datano data
David Smith
Executive VP & Head of Chemical Operations6.4yrsno datano data
Tse-I Lin
VP of Early Compound Development & Belgian Site Head3yrsno datano data
Hardean Achneck
Chief Medical Officerless than a yearno datano data

5.5yrs

Average Tenure

60yo

Average Age

Experienced Management: ALGS's management team is seasoned and experienced (5.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Lawrence Blatt
CEO, President & Chairman of the Board6.9yrsUS$1.34m2.32%
$ 2.9m
Carole Nuechterlein
Independent Director6.4yrsUS$12.90kno data
K. Hirth
Independent Director6.4yrsUS$60.40k0.064%
$ 81.6k
James Scopa
Independent Director3.8yrsUS$67.90k0.20%
$ 250.7k
Heather Preston
Independent Directorless than a yearno datano data
Margarita Chavez
Independent Directorless than a yearno datano data
Bridget Martell
Independent Director3.2yrsUS$52.90kno data

3.8yrs

Average Tenure

62yo

Average Age

Experienced Board: ALGS's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/19 10:30
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aligos Therapeutics, Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alethia YoungCantor Fitzgerald & Co.
Antonio ArceH.C. Wainwright & Co.
Michael YeeJefferies LLC